Atopic dermatitis is one of the most common skin diseases in dogs.
 

As in humans, it is associated with a genetic predisposition to develop hypersensitivity reactions to common environmental allergens.
 

Treatment of this condition can present quite a challenge to the veterinary practitioner, since it is typically multifaceted and treatment response is often unpredictable.
 

We at Novartis Animal Health understand the importance of properly diagnosing and treating this common disease and have created this technical monograph to serve as a definitive guide to canine atopic disease.
 

We are proud to introduce ATOPICA® (Cyclosporine capsules, USP) MODIFIED, the first FDA-approved oral medication specifically designed for targeted control of canine atopic dermatitis. If you have questions, please contact your Novartis representative or Novartis Animal Health Technical Services at 1-800-637-0281.
 

Note: Please be patient while downloading Technical Monograph (797 KB)...